Gene module is target-rich environment for Alzheimer's pathology, cognitive decline

A team of NIA-supported researchers, as part of the Accelerating Medicines Partnership for Alzheimer's disease (AMP-AD) Target Discovery and Preclinical Validation consortium has zeroed in on several potential therapeutic targets from a cluster of genes associated with Alzheimer’s disease brain pathology and cognitive decline.
The finding is an important milestone for the AMP-AD program and Alzheimer’s disease research in general, as it demonstrates the power of systems-based modelling approaches to identify causal associations between entire networks of genes and various pathologic and/or clinical traits for Alzheimer’s disease. Known as gene module-trait network (MTN) analysis, this technique gives a more holistic view of molecular targets than traditional single gene associations, focusing on disease-relevant patterns of co-expressed genes that can enable entire gene networks to be therapeutically modulated to more robustly modify the disease process.

#Alzheimers2018 is scheduled to be held in December 03-04, 2018 at Madrid, Spain.
To know more download our brochure via: https://bit.ly/2Ld1keT

Comments

Popular posts from this blog

There is mounting evidence that herpes leads to Alzheimers Disease

AI algorithm accurately predicts Alzheimer’s disease onset

Evidence Mounts That Germs May Cause Alzheimer's